Author: PWeekly

The American Society of Hematology Annual Meeting & Exposition (ASH 2021) Will be held December 11-14, 2021 at the Georgia World Congress Center in Atlanta, as well as virtually. The “premier event in malignant and...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Representative Rosa DeLauro (D-CT) for her outstanding support of hematology research at the 2021 ASH Annual Meeting, December 11-14, in Atlanta,...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) for his...

MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Physician’s Weekly spoke with...

In the phase IV open-label PROTECT trial of pegloticase therapy (pegylated recombinant uricase) in treating severe gout in renal transplant recipients, 89% of patients achieved the primary endpoint of serum uric acid (sUA) less...

We recently spoke with Andrea Lora Kossler, MD, FACS, from the Byers Eye Institute at Stanford University about results from the study “Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease,” which she...

A post-hoc analysis of data from the ORION-9, ORION-10, and ORION-11 trials, presented during the 2021 American Heart Association (AHA) Scientific Sessions, showed that inclisiran treatment every 6 months resulted in effective...

According to a biomarker sub-study of patients with heart failure with reduced ejection fraction (HFrEF) from the DAPA-HF trial, presented during the 2021 American Heart Association (AHA) Scientific Sessions, increases in...

Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...

A genome-wide association study (GWAS) of dry eye (DE) suggests DE-associated single nucleotide polymorphisms (SNPs) are correlated with increased ocular pain and comorbidities, but not with DE signs, according to study...

Several significant advances have occurred in dry eye disease (DED) treatment in recent years, according to Amy Lin, MD. Including treatments with novel mechanisms of action and delivery systems. “This news is very exciting for...

The COVID-19 pandemic resulted in unforeseen changes in healthcare delivery for patients with MS, and the pandemic’s swift progression led to a knowledge gap about how the virus has impacted practice patterns for MS clinicians,...

In a dialysis-dependent population, patients with gout showed a higher cardiovascular comorbidity burden and an increased risk of hospitalization and mortality, compared with patients without gout. In addition, older age,...

Concomitant use of immunomodulators prolonged the effectiveness of pegloticase in patients with uncontrolled gout. Results from a large observational study were consistent with previously conducted smaller trials.1 The...